Precision Medicine According to Paul Mampilly is the Next Big Thing in Investments

Paul Mampilly is a hedge fund consultant and a long-term investor. He serves as a senior editor at Banyan Hill Publishing for Profits Unlimited newsletter, and two trading services True Momentum, and Extreme Fortunes. He writes a weekly newsletter column for Banyan since joining in 2016. His current endeavors center on helping ordinary Americans create wealth by investing in growth, small-cap stocks, unique opportunities, and technology. These numerous responsibilities and efforts are fueled by an extensive engagement and experience in investment and financial world. With over 25years in the investment sector, a former Wall Street insider, a hedge fund manager, and investor, Mampilly advice can be relied on. Read this article at Daily Forex Report.

Before joining Banyan, Paul Mampilly previously worked at Stansberry Research as the editor of Professional Speculator in 2015. In 2003, he founded The Capuchin Group and served as its Publisher, Editor, and author. His work experience stems from when he started working as an assistant Portfolio manager at Bankers Trust. He became a money manager at Sear, Swiss Bank, and Royal Bank of Scotland. He is interested and follows the stock market, as well as identifying small firms coming up with innovative business models and products and that are worth his investing. Following his $88 million gain from a $50 million investment, he won the Templeton Foundation Investment Competition in 2009.


His view on cryptocurrency and Bitcoin is that the bubble will burst in time though he is not specific on when. He says that just like the 1999 stock market explosion, wise investors should realize there is market greed that is pushing the price higher. They ought to sell before the bubble burst since they stand at a profit already before it collapses and they lose. Paul Mampilly advises that Bitcoin, Ethereum, and other cryptocurrencies will crash. He says that the problem with most investors who remain attached to the high cryptocurrency prices is that they fail to note when to sell as prices peak.

He has advised potential investors looking for opportunities to invest in precision medicine. His Profits Unlimited newsletter, which is the entry-level ($97 per year) stock picking letter for Banyan Hill offers more on this and other investment ideas. Paul Mampilly says that precision medicine involves looking at a person’s DNA and coming up with medical interventions that match their genetic makeup.

The implication of this new technology, if it comes to fruition, is that chronic diseases such as Alzheimer’s, heart disease, Parkinson’s and diabetes can be ultimately dealt with through DNA analysis. Paul Mampilly identifies Myriad Genetics (MYGN) as the company to invest in when it comes to precision medicine. Read more about Paul on

Comments are closed.